Study of Decreasing Kinetics of the Leptospiremia During Antibiotic Treatment of Leptospirosis in Martinique (Ciné LEPTO)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02000635|
Recruitment Status : Recruiting
First Posted : December 4, 2013
Last Update Posted : March 20, 2018
The leptospirosis evolves on an endemic mode in French West Indies and its incidence in 2011 was de 61/100 000 inhabitants, 100 times more than the metropolitan France's incidence (0,47/100 000). If cases can arise all year long, periods of heavy rainfall are associated with the arisen of epidemic peaks Clinical presentation of leptospirosis include a wide range of symptoms: the most frequent form is a flu-like syndrome but more severe forms are described as meningitis, uveitis and classical severe presentation such as lung bleedings and liver-kidneys infringement (syndrome of Weil) which constitute the most severe forms of the disease.
Currently , Polymerase chain reaction (PCR) is the only test who can provide a diagnostic confirmation during the first week of development and before the appearance of the first antibody.
If the microagglutination test (MAT) is considered the gold standard test for diagnosis of leptospirosis. However it requires rending samples to the referent National center for the leptospirosis at Pasteur Institute in Paris while the antibodies do not appears until the second week of illness. A second sample is required 15 days after the first one, to confirm the diagnosis.
In clinical practice , the technique of real-time PCR for the detection and quantification of pathogenic Leptospira during the first week of illness . The technique of diagnosis of leptospirosis by real-time PCR has been implemented and tested in 2007 at the University Hospital of Martinique and providing to the clinicians from 2008. The optimal duration of antibiotic therapy has not been studied and experts now recommend for a 7 to 10 days, regardless of the severity of the disease. The evolution of leptospiremia treated patients has not been studied to date.
|Condition or disease||Intervention/treatment|
|Leptospirosis||Other: Quantitative PCR performed at H0 , H24, H48 , H72, 7th day and 14th day|
|Study Type :||Observational|
|Estimated Enrollment :||50 participants|
|Official Title:||Study of Decreasing Kinetics of the Leptospiremia During Antibiotic Treatment of Leptospirosis in Martinique|
|Study Start Date :||December 2014|
|Estimated Primary Completion Date :||February 2021|
|Estimated Study Completion Date :||March 2021|
Patient with a diagnosis of leptospirosis confirmed by PCR in the five first day
Other: Quantitative PCR performed at H0 , H24, H48 , H72, 7th day and 14th day
- Change of concentration of leptospires in the blood during the first 7 days after the recruitment. [ Time Frame: At the recruitment, 24 hours, 48 hours 72 hours and the 7th day after the recruitment ]For each patient, 5-6 quantitative PCR will be performed during the treatment at : The inclusion , 24 hours after the recruitment, 48 hours , 72 hours and the 7th day after the recruitment . In case of positive result of the quantitative PCR at the 7th day of treatment, late charge will be made around the 14th day.
Biospecimen Retention: Samples With DNA
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02000635
|Contact: Janick JEAN-MARIE, Master||0596592697 ext +email@example.com|
|Chu de Martinique||Recruiting|
|Fort de France, Martinique, 97200|
|Contact: Janick JEAN-MARIE, Master 0596592697 ext +596 firstname.lastname@example.org|
|Principal Investigator: Patrick Hochedez, MD|
|Principal Investigator:||Patrick Hochedez, MD||CHU de Fort de France|